<?xml version="1.0" encoding="UTF-8"?>
<p id="para0026">However, specific resistance mutations to pimodivir emerged in the PB2 protein of 6.4% of trial participants, indicating that the genetic barrier to viral escape from the drug is low. Compared to standard-of-care, baloxavir marboxil and ribonucleoside analogs in development, another substantial limitation of pimodivir is a narrowed antiviral indication spectrum. Exclusively IAVs are susceptible to the drug,
 <xref rid="bib0119" ref-type="bibr">
  <sup>119</sup>
 </xref> restricting its use to only 1 of the 2 clinically-significant influenza virus genera.
</p>
